1. Medicines
  2. Haematology
  3. REVOLADE® (eltrombopag olamine)

Prescribing information

REVOLADE® (eltrombopag olamine)

What is REVOLADE?

REVOLADE is a thrombopoietin receptor agonist or TPO-RA with a targeted mechanism of action that increases platelet production without compromising the immune system1,2

REVOLADE is a once-daily film-coated tablet (FCT) for the treatment of patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatment (e.g. cortciosteroids, immunoglobulins).1

 

What can REVOLADE offer your ITP patients?

a target

Platelet control without immunosuppression1,2

Learn more

a tick list

Across 5 clinical trials3–7
In over 5000 global subjects8*

Learn more

a shield with a large tick inside it

10 years of real-world
clinical practice1

Learn more

 

Choose REVOLADE for your ITP patients with confidence1–8

 
FCT, film-coated tablet; ITP, immune thrombocytopenia; TPO-RA, thrombopoietin receptor agonist.
*A total of 5541 subjects have been exposed to REVOLADE since the development international birthdate in October of 2004.8
References
  1. REVOLADE Summary of Product Characteristics.
  2. Kuter D. Int J Hematol. 2013;98:10–23.
  3. Wong R, et al. Blood. 2017;130:2527–2536.
  4. Cheng G, et al. Lancet. 2011;377:393–402.
  5. Bussel J, et al. Br J Haematol. 2013;160:538–546.
  6. Bussel J, et al. Lancet. 2015;2:315–325.
  7. Grainger J, et al. Lancet. 2015;386:1649–1658.
  8. Data on file REVDOFPATIENTYEARS.
 
IE | May 2022 | 174745

Click here for Product Information

Rate this content: 
No votes yet
Print
×

Ask Speakers

×

Medical Information Request

Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email:[email protected] or by calling 01 2080 612.